Outcomes of dosage adjustments used to manage antiretroviral drug interactions

Clinical Infectious Diseases

Volumn 45, Issue 7, 2007, Pages 933-936

  Park Wyllie, Laura Y ^a,b   Levine, Mitchell A ^e,f   Holbrook, Anne ^e,f   Thabane, Lehana ^e,f   Antoniou, Tony ^b   Yoong, Deborah ^b   Kam, Derek ^a   Bayoumi, Ahmed M ^a,b,c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RIFABUTIN; RITONAVIR; SAQUINAVIR;

ADULT; ARTHRALGIA; ARTICLE; BONE MARROW DEPRESSION; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFECT; DRUG ERUPTION; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROPSYCHIATRIC SYMPTOM; PRIORITY JOURNAL; TRANSAMINITIS; TREATMENT OUTCOME; UVEITIS; VIRUS LOAD; CANADA; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; LONGITUDINAL STUDY; MEDICAL AUDIT; MIDDLE AGED;

ANTI-RETROVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICAL AUDIT; MIDDLE AGED; ONTARIO; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34848830836     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521252     Document Type: Article

References (21)

1. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42:223-82.
2. Tseng AL. Medical information for health care professionals: drug interaction tables. Available at: http://www.tthhivclinic.com/. Accessed 30 June 2006.
3. Haas DW, Arathoon E, Thompson MA, et al. Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS 2000; 14:1973-8.
4. Hamzeh FM, Benson C, Gerber J, et al. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003; 73:159-69.
5. Gerbert B, Caspers N, Moe J, Clanon K, Abercrombie P, Herzig K. The mysteries and demands of HIV care: qualitative analyses of HIV specialists' views on their expertise. AIDS Care 2004; 16:363-76.
6. Protocol Merck-069. An open label, randomized, multicenter study comparing the efficacy and safety of indinavir (800 mg/8h vs 1200 mg/12h), in combination with zidovudine and lamivudine. Westpoint, PA: Merck 1998.
7. Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron DW. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2001; 70:149-58.
8. Kearney B, Damle B, Plummer A, et al. Tenofovir DF (TDF) and didanosine EC (ddI EC): investigation of pharmacokinetic (PK) drug-drug and drug-food interactions [abstract LbPeB 9026]. In: Program and abstracts of the 14th International AIDS Conference (Barcelona, Spain). 2002.
9. Kearney B, Flaherty J, Sayre J, Wolf J, Coakley D. A multiple-dose, randomized, cross-over drug interaction study between tenofovir DF and lamivudine or didanosine [abstract 337]. In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires, Argentina). 2001.
10. Young B, Baker R, Wood K. Safety and tolerability of didanosine combined with tenofovir DF in ambulatory HIV-1 infected adult individuals [abstract F16/5]. In: Program and abstracts of the 9th European AIDS Conference (Warsaw, Poland). 2003.
11. Barrios A, Maida I, Perez-Saleme L, et al. Safety and efficacy of combinations based on didanosine 400 mg OD plus tenofovir 300 mg OD [abstract H-847]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, Illinois). Washington, DC: American Society for Microbiology, 2003.
12. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344:984-96.
13. Back DJ, Khoo SH. The role of clinical pharmacology in optimizing antiretroviral therapy. Br J Clin Pharmacol 2003; 55:473-6.
14. Forte T, Bayoumi AM, Remis RS, et al. Representativeness of the HIV Ontario Observational Database [abstract 337]. In: Program and abstracts of the 12th Annual Canadian Conference on HIV/AIDS Research (Halifax, Nova Scotia). 2003.
15. World Health Organization (WHO) Collaborating Centre for International Drug Monitoring. International monitoring of adverse reactions to drugs: adverse reaction terminology. Geneva: WHO, 1992.
16. Raboud JM, Abdurrahman ZB, Major C, et al. Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada. J Acquir Immune Defic Syndr 2005; 39:327-32.
17. The Ontario HIV Treatment Network. Ontario HIV Cohort Study. Available at: http://www.ohtn.on.ca. Accessed 13 August 2007.
18. Sheehan NL, Kelly DV, Tseng AL, van Heeswijk RP, Beique LC, Hughes CA. Evaluation of HIV drug interaction Web sites. Ann Pharmacother 2003; 37:1577-86.
19. University of Liverpool. Drug interaction charts. Available at: http://www.hiv-druginteractions.org/. Accessed 6 September 2006.
20. University of California San Francisco School of Medicine. Database of antiretroviral drug interactions. Available at: http://www.hivinsite.ucsf.edu/. Accessed 6 September 2006.
21. Gagnon A, Therrien, R. HIV medication guide. Available at: http://www.hivmedicationguide.com. Accessed 6 September 2006.